P. Renard

Nivolumab to control molecular response in chronic myeloid leukemia.

P. Rousselot, P. Saiag, M. Spentchian, 2018, Leukemia research.

Clinical and biological characterization of 20 patients with TANGO2 deficiency indicates novel triggers of metabolic crises and no primary energetic defect

P. van Endert, M. Polak, N. Boddaert, 2020, Journal of inherited metabolic disease.

Compromised mitochondrial quality control triggers lipin1-related rhabdomyolysis

P. van Endert, Y. Hamel, M. Rodero, 2021, Cell reports. Medicine.

Hydroxychloroquine sulfate: A novel treatment for lipin-1 deficiency?

P. van Endert, Nicolas Goudin, P. de Lonlay, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Contribution of collegial support meetings (CSM) in the management of complex situations of patients with advanced cancer

S. Dauchy, F. Scotté, B. Verret, 2023, Supportive Care in Cancer.

Decisions about treatment with targeted therapies in a palliative care unit: A case series.

S. Dauchy, F. Scotté, L. Vigouret-Viant, 2022, Palliative & supportive care.

Systemic corticosteroids for the treatment of acute episodes of rhabdomyolysis in lipin‐1‐deficient patients

P. de Lonlay, A. Brassier, S. Renolleau, 2023, Journal of inherited metabolic disease.

[Implementation of a multimodal strategy for information and collection of advance directives in a comprehensive cancer center].

C. Mateus, A. Rieutord, N. Fournier-Bidoz, 2023, Bulletin du cancer.